Progress toward personalized treatment of rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 440-442

  Keith, M P ^a   Edison, J D ^a   Gilliland, W R ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE MONOPHOSPHATE DEAMINASE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INOSINE TRIPHOSPHATE PHOSPHORYLASE; METHOTREXATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; TREATMENT OUTCOME;

EID: 84866614151     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.124     Document Type: Article

References (5)

1. Meyer, U.A. Personalized medicine: a personal view. Clin Pharmacol Ther. 91, 373-375 (2012).
2. Wessels, J.A. et al.; Pharmacogenetics collaborative Research Group. A clinical pharmacogenetic model to predict the efcacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56, 1765-1775 (2007).
3. Lee, Y.C., Cui, J., Costenbader, K.H., Shadick, N.A., Weinblatt, M.E. & Karlson, E.W. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford). 48, 613-617 (2009).
4. Ranganathan, P. et al. Methotrexate (MtX) pathway gene polymorphisms and their efects on MtX toxicity in caucasian and African American patients with rheumatoid arthritis. J. Rheumatol. 35, 572-579 (2008).
5. Kooloos, W.M., Wessels, J.A., van der Straaten, t., Allaart, C.F., Huizinga, t.W. & Guchelaar, H.J. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11, 163-175 (2010).